Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. HDL cholesterol and non-cardiovascular disease: a narrative review

    Research output: Contribution to journalReviewpeer-review

  2. The Role of Leptin in Fetal Growth during Pre-Eclampsia

    Research output: Contribution to journalReviewpeer-review

  3. A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Regional Differences in Neuroinflammation-Associated Gene Expression in the Brain of Sporadic Creutzfeldt-Jakob Disease Patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prolonging fixation time of an alternative fixative to formalin for dermatological samples using standard laboratory protocols

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Regional Differences in Neuroinflammation-Associated Gene Expression in the Brain of Sporadic Creutzfeldt-Jakob Disease Patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The molecular profile of mucosal melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Treatment Algorithm for Advanced ALK-Rearranged NSCLC

    Research output: Contribution to journalLetterpeer-review

View graph of relations

Anaplastic lymphoma-kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) is prone to developing heterogeneous, only partly known mechanisms of resistance to ALK-tyrosine-kinase-inhibitors (ALK-TKIs). We present a case of a 38-year old male, who never smoked with disseminated ALK-rearranged (EML4 (20) - ALK (20) fusion variant 2) lung adenocarcinoma, who received four sequentially different ALK-TKIs and two lines of chemotherapy in-between. We observed significant clinical benefit by the first three ALK-TKIs (Crizotinib, Ceritinib, Alectinib) and chemotherapy with Pemetrexed, resulting in overall survival over 3 years. Longitudinal assessment of progressions by rebiopsies from hepatic metastases showed different mechanisms of resistance to each ALK-TKI, including secondary ALK-mutations and the downstream p.V600E BRAF-mutation that had not been linked to second-generation ALK-TKIs before. Ultimately, in connection with terminal rapid progression and resistance to Alectinib and Lorlatinib, we identified phenotypical epithelial-mesenchymal transition (EMT) of newly occurred metastatic cells, a phenomenon not previously related to these two ALK-TKIs. This resistance heterogeneity suggests a continuously changing disease state. Sequential use of different generation's ALK-TKIs and combination therapies may yield prolonged responses with satisfactory quality of life in patients with advanced ALK-positive NSCLC. However, the development of EMT is a major hurdle and may explain rapid disease progression and lack of response to continued ALK-inhibition.

Original languageEnglish
JournalInternational Journal of Molecular Sciences
Volume21
Issue number8
Pages (from-to)2847
ISSN1661-6596
DOIs
Publication statusPublished - 19 Apr 2020

    Research areas

  • Alectinib, Alk-rearranged nsclc, Alk-tki resistance, Braf-mutation, Ceritinib, Crizotinib, Emt, Lorlatinib

ID: 59998373